Focal Neurologic Deficit

References

1. ↵
   Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–87

   CrossRefPubMedWeb of Science
2. ↵
   Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study—a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003–11

   CrossRefPubMedWeb of Science
3. ↵
   Fiebach JB, Schellinger PD, Gass A, et al. Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke 2004;35:502–06

   Abstract/FREE Full Text
4. ↵
   Kidwell CS, Chalela JA, Saver JL, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004;292:1823–30

   CrossRefPubMedWeb of Science
5. ↵
   Brown G, Warren M, Williams JE, et al. Cranial computed tomography of elderly patients: an evaluation of its use in acute neurological presentations. Age Ageing 1993;22:240–43

   Abstract/FREE Full Text
6. ↵
   Yuh WT, Tali ET, Nguyen HD, et al. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 1995;16:373–80

   Abstract/FREE Full Text
7. ↵
   Yousry TA, Schmid UD, Jassoy AG, et al. Topography of the cortical motor hand area: prospective study with functional MR imaging and direct motor mapping at surgery. Radiology 1995;195:23–29

   PubMedWeb of Science
8. ↵
   Buchpiguel CA, Alavi JB, Alavi A, et al. PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain. J Nucl Med 1995;36:159–64

   Abstract/FREE Full Text
9. ↵
   Kim YJ, Chang KH, Song IC, et al. Brain abscess and necrotic or cystic brain tumor: discrimination with signal intensity on diffusion-weighted MR imaging. AJR Am J Roentgenol 1998;171:1487–90

   CrossRefPubMedWeb of Science
10. ↵
    Younis RT, Anand VK, Davidson B. The role of computed tomography and magnetic resonance imaging in patients with sinusitis with complications. Laryngoscope 2002;112:224–29

    CrossRefPubMedWeb of Science
11. ↵
    Chang L, Miller BL, McBride D, et al. Brain lesions in patients with AIDS: H-1 MR spectroscopy. Radiology 1995;197:525–31. Erratum in: Radiology 1996;198:586

    PubMedWeb of Science
12. ↵
    Ernst TM, Chang L, Witt MD, et al. Cerebral toxoplasmosis and lymphoma in AIDS: perfusion MR imaging experience in 13 patients. Radiology 1998;208:663–69

    PubMed
13. ↵
    Arnason BG. Interferon beta in multiple sclerosis. Clin Immunol Immunopathol 1996;81:1–11

    CrossRefPubMedWeb of Science
14. Arnason BG, Toscas A, Dayal A, et al. Role of interferons in demyelinating diseases. J Neural Transm Suppl 1997;49:117–23

    PubMed
15. Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41:385–91

    CrossRefPubMedWeb of Science
16. Rudick RA, Cohen JA, Weinstock-Guttman B, et al. Management of multiple sclerosis. N Engl J Med 1997;337:1604–11

    CrossRefPubMedWeb of Science
17. ↵
    Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278–85

    CrossRefPubMedWeb of Science
18. ↵
    Ertl-Wagner BB, Reith W, Sartor K. Low field-low cost: can low-field magnetic resonance systems replace high-field magnetic resonance systems in the diagnostic assessment of multiple sclerosis patients? Eur Radiol 2001;11:1490–94

    CrossRefPubMed
19. ↵
    Goodkin DE. MS clinical trial design for the future. Mult Scler 1996;1:393–99

    PubMed
20. ↵
    Tubridy N, Ader HJ, Barkhof F, et al. Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups. J Neurol Neurosurg Psychiatry 1998;64:50–55

    Abstract/FREE Full Text
21. ↵
    Filippi M, Campi A, Martinelli V, et al. Brain and spinal cord MR in benign multiple sclerosis: a follow-up study. J Neurol Sci 1996;143:143–49

    CrossRefPubMedWeb of Science
22. Filippi M, Capra R, Campi A, et al. Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:526–30

    Abstract/FREE Full Text
23. Silver NC, Good CD, Barker GJ, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis: effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 1997;120 (pt 7):1149–61

    Abstract/FREE Full Text
24. Simon JH. Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. J Magn Reson Imaging 1997;7:29–37

    PubMedWeb of Science
25. ↵
    van Waesberghe JH, Castelijns JA, Roser W, et al. Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. AJNR Am J Neuroradiol 1997;18:1279–85

    Abstract
26. ↵
    Narayana PA, Doyle TJ, Lai D, et al. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998;43:56–71

    CrossRefPubMedWeb of Science